Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX NAMES SHAUN MARTIN AS DIRECTOR, PRE-CLINICAL DEVELOPMENT

ROCHESTER, NY - Vaccinex, Inc. announced today the hiring of Dr. Shaun Martin as Director, Pre-clinical Development. Dr. Martin will become part of the team responsible for directing the transition of discovery-stage antibodies into lead drug candidates suitable for pre-clinical development. In addition, he will use his broad industry knowledge and business experience to assist Vaccinex in developing commercial relationships with biotechnology and pharmaceutical companies involved in antibody development. Dr. Martin has over 10 years of biotechnology experience and most recently was Senior Director, Business Development for MDS Pharma Services, one of the world's largest Contract Research Organizations ("CRO").

Maurice Zauderer, Vaccinex's President and CEO, commented, "Shaun has had an extensive career in designing bio-safety programs for large therapeutic molecules, including antibodies, and he has gained significant experience in facilitating the complex processes involved in evaluating the pharmacology and toxicology of therapeutic drug candidates. We are very fortunate to have him as a new member of our development team."

Dr. Martin received a BS in Biological Sciences from the University of Lancaster, UK, and a Ph.D. in Physiology from the University of Liverpool, UK. He did post-doctorate research at the University of Liverpool where he investigated intracellular cell signaling mechanisms and the control of insulin secretion and thyroid function. He later joined the University of Rochester School of Medicine as a Post-doctoral Fellow in Pharmacology, conducting research in the areas of receptor pharmacology and intracellular signaling mechanisms.

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Using its proprietary vaccinia vector technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. Moreover, this technology offers the potential to generate antibodies against difficult targets such as homologous proteins and multi-pass membrane receptors. The company has received more than $10 million in research grants awards and over $20 million in venture funding. Vaccinex is headquartered in Rochester, NY and currently employs 40 scientists and staff. For additional information, please visit the company's website at www.vaccinex.com.

CONTACTS:
Vaccinex, Inc. -Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105) - rwatkins@vaccinex.com

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX NAMES SHAUN MARTIN AS DIRECTOR, PRE-CLINICAL DEVELOPMENT ROCHESTER, NY - Vaccinex, Inc. announced today the hiring of Dr. Shaun Martin as Director, Pre-clinical Development. Dr. Martin will become part of the team responsible for directing the transition of discovery-stage antibodies into lead drug candidates suitable for pre-clinical development. In addition, he will use his broad industry knowledge and business experience to assist Vaccinex in developing commercial relationships with biotechnology and pharmaceutical companies involved in antibody development. Dr. Martin has over 10 years of biotechnology experience and most recently was Senior Director, Business Development for MDS Pharma Services, one of the world's largest Contract Research Organizations ("CRO"). Maurice Zauderer, Vaccinex's President and CEO, commented, "Shaun has had an extensive career in designing bio-safety programs for large therapeutic molecules, including antibodies, and he has gained significant experience in facilitating the complex processes involved in evaluating the pharmacology and toxicology of therapeutic drug candidates. We are very fortunate to have him as a new member of our development team." Dr. Martin received a BS in Biological Sciences from the University of Lancaster, UK, and a Ph.D. in Physiology from the University of Liverpool, UK. He did post-doctorate research at the University of Liverpool where he investigated intracellular cell signaling mechanisms and the control of insulin secretion and thyroid function. He later joined the University of Rochester School of Medicine as a Post-doctoral Fellow in Pharmacology, conducting research in the areas of receptor pharmacology and intracellular signaling mechanisms. Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Using its proprietary vaccinia vector technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. Moreover, this technology offers the potential to generate antibodies against difficult targets such as homologous proteins and multi-pass membrane receptors. The company has received more than $10 million in research grants awards and over $20 million in venture funding. Vaccinex is headquartered in Rochester, NY and currently employs 40 scientists and staff. For additional information, please visit the company's website at www.vaccinex.com. CONTACTS: Vaccinex, Inc. -Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105) - rwatkins@vaccinex.com Back to News Archive Copyright © 2008 Vaccinex, Inc.